UA73101C2 - Antagonist of serotonin receptor encapsulated by biodegradable polymer and method for its manufacture - Google Patents

Antagonist of serotonin receptor encapsulated by biodegradable polymer and method for its manufacture Download PDF

Info

Publication number: UA73101C2
Authority: UA; Ukraine
Prior art keywords: specified; indicated; polymer; pharmaceutically active; active molecule
Prior art date: 1998-12-16

Application number

UA2001064165A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Aventic Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-16

Filing date

1999-11-22

Publication date

2005-06-15

1999-11-22 Application filed by Aventic Pharmaceuticals Inc filed Critical Aventic Pharmaceuticals Inc

2005-06-15 Publication of UA73101C2 publication Critical patent/UA73101C2/uk

Links

238000000034 method Methods 0.000 title claims abstract description 99
229920002988 biodegradable polymer Polymers 0.000 title claims abstract description 28
239000004621 biodegradable polymer Substances 0.000 title claims abstract description 28
239000005557 antagonist Substances 0.000 title claims abstract description 6
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 title claims 3
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 title claims 3
238000004519 manufacturing process Methods 0.000 title abstract description 7
229920000642 polymer Polymers 0.000 claims abstract description 109
239000000203 mixture Substances 0.000 claims abstract description 85
239000011859 microparticle Substances 0.000 claims abstract description 51
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 45
229920001577 copolymer Polymers 0.000 claims abstract description 18
239000002552 dosage form Substances 0.000 claims abstract description 13
239000006104 solid solution Substances 0.000 claims abstract description 13
208000020925 Bipolar disease Diseases 0.000 claims abstract description 10
208000028017 Psychotic disease Diseases 0.000 claims abstract description 10
206010013663 drug dependence Diseases 0.000 claims abstract description 8
208000011117 substance-related disease Diseases 0.000 claims abstract description 8
238000002156 mixing Methods 0.000 claims description 51
150000001875 compounds Chemical class 0.000 claims description 40
229940125904 compound 1 Drugs 0.000 claims description 31
230000000694 effects Effects 0.000 claims description 28
230000015572 biosynthetic process Effects 0.000 claims description 25
239000000243 solution Substances 0.000 claims description 22
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 18
238000009826 distribution Methods 0.000 claims description 16
238000013268 sustained release Methods 0.000 claims description 15
239000012730 sustained-release form Substances 0.000 claims description 15
230000009477 glass transition Effects 0.000 claims description 13
239000008187 granular material Substances 0.000 claims description 12
229920000728 polyester Polymers 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 12
229940076279 serotonin Drugs 0.000 claims description 10
208000020401 Depressive disease Diseases 0.000 claims description 8
239000003420 antiserotonin agent Substances 0.000 claims description 8
102000005962 receptors Human genes 0.000 claims description 8
108020003175 receptors Proteins 0.000 claims description 8
239000000725 suspension Substances 0.000 claims description 8
208000019901 Anxiety disease Diseases 0.000 claims description 7
230000036506 anxiety Effects 0.000 claims description 7
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 6
229940121356 serotonin receptor antagonist Drugs 0.000 claims description 6
238000005469 granulation Methods 0.000 claims description 5
230000003179 granulation Effects 0.000 claims description 5
239000008240 homogeneous mixture Substances 0.000 claims description 5
208000019116 sleep disease Diseases 0.000 claims description 5
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 4
230000005764 inhibitory process Effects 0.000 claims description 4
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical group CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 4
208000003890 Coronary Vasospasm Diseases 0.000 claims description 3
208000007536 Thrombosis Diseases 0.000 claims description 3
206010002383 Angina Pectoris Diseases 0.000 claims description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 2
239000004952 Polyamide Substances 0.000 claims description 2
229920002732 Polyanhydride Polymers 0.000 claims description 2
229920000954 Polyglycolide Polymers 0.000 claims description 2
229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 2
229920001710 Polyorthoester Polymers 0.000 claims description 2
239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 2
229920000747 poly(lactic acid) Polymers 0.000 claims description 2
229920002627 poly(phosphazenes) Polymers 0.000 claims description 2
229920002647 polyamide Polymers 0.000 claims description 2
229920001610 polycaprolactone Polymers 0.000 claims description 2
239000004632 polycaprolactone Substances 0.000 claims description 2
229920000515 polycarbonate Polymers 0.000 claims description 2
239000004417 polycarbonate Substances 0.000 claims description 2
229940102213 injectable suspension Drugs 0.000 claims 2
238000003801 milling Methods 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 19
238000000227 grinding Methods 0.000 abstract description 18
239000004480 active ingredient Substances 0.000 abstract description 15
238000001125 extrusion Methods 0.000 abstract description 12
201000000980 schizophrenia Diseases 0.000 abstract description 11
238000007580 dry-mixing Methods 0.000 abstract description 7
239000013543 active substance Substances 0.000 abstract description 6
238000002347 injection Methods 0.000 abstract description 5
239000007924 injection Substances 0.000 abstract description 5
230000008569 process Effects 0.000 abstract description 4
208000022531 anorexia Diseases 0.000 abstract description 3
206010061428 decreased appetite Diseases 0.000 abstract description 3
238000013270 controlled release Methods 0.000 abstract description 2
102000049773 5-HT2A Serotonin Receptor Human genes 0.000 abstract 1
108010072564 5-HT2A Serotonin Receptor Proteins 0.000 abstract 1
229940079593 drug Drugs 0.000 description 34
239000003814 drug Substances 0.000 description 34
241001465754 Metazoa Species 0.000 description 30
239000011159 matrix material Substances 0.000 description 28
229930006000 Sucrose Natural products 0.000 description 24
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 24
239000005720 sucrose Substances 0.000 description 24
238000002474 experimental method Methods 0.000 description 22
239000000463 material Substances 0.000 description 22
239000002245 particle Substances 0.000 description 19
230000008901 benefit Effects 0.000 description 16
210000003169 central nervous system Anatomy 0.000 description 11
208000035475 disorder Diseases 0.000 description 11
238000002844 melting Methods 0.000 description 11
239000002904 solvent Substances 0.000 description 11
239000000155 melt Substances 0.000 description 10
230000008018 melting Effects 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
238000000113 differential scanning calorimetry Methods 0.000 description 9
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 9
230000002035 prolonged effect Effects 0.000 description 9
238000005809 transesterification reaction Methods 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
238000005481 NMR spectroscopy Methods 0.000 description 8
239000000523 sample Substances 0.000 description 8
238000004626 scanning electron microscopy Methods 0.000 description 8
238000012360 testing method Methods 0.000 description 8
208000024891 symptom Diseases 0.000 description 7
206010026749 Mania Diseases 0.000 description 6
201000010099 disease Diseases 0.000 description 6
238000004090 dissolution Methods 0.000 description 6
235000013305 food Nutrition 0.000 description 6
239000011521 glass Substances 0.000 description 6
238000004128 high performance liquid chromatography Methods 0.000 description 6
208000024714 major depressive disease Diseases 0.000 description 6
238000004458 analytical method Methods 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
238000000354 decomposition reaction Methods 0.000 description 5
239000003937 drug carrier Substances 0.000 description 5
238000001035 drying Methods 0.000 description 5
239000000945 filler Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
238000010438 heat treatment Methods 0.000 description 5
229960004801 imipramine Drugs 0.000 description 5
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 5
230000003993 interaction Effects 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 5
239000000843 powder Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
206010012374 Depressed mood Diseases 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
238000013329 compounding Methods 0.000 description 4
230000007423 decrease Effects 0.000 description 4
229960003638 dopamine Drugs 0.000 description 4
238000005227 gel permeation chromatography Methods 0.000 description 4
239000003094 microcapsule Substances 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
238000007911 parenteral administration Methods 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
239000000047 product Substances 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
206010012239 Delusion Diseases 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
238000001816 cooling Methods 0.000 description 3
231100000868 delusion Toxicity 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
206010022437 insomnia Diseases 0.000 description 3
239000004005 microsphere Substances 0.000 description 3
239000012299 nitrogen atmosphere Substances 0.000 description 3
230000006977 prepulse inhibition Effects 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000007962 solid dispersion Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
208000007415 Anhedonia Diseases 0.000 description 2
208000000103 Anorexia Nervosa Diseases 0.000 description 2
235000017060 Arachis glabrata Nutrition 0.000 description 2
244000105624 Arachis hypogaea Species 0.000 description 2
235000010777 Arachis hypogaea Nutrition 0.000 description 2
235000018262 Arachis monticola Nutrition 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
208000001640 Fibromyalgia Diseases 0.000 description 2
208000004547 Hallucinations Diseases 0.000 description 2
206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
208000001431 Psychomotor Agitation Diseases 0.000 description 2
208000003782 Raynaud disease Diseases 0.000 description 2
208000012322 Raynaud phenomenon Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000012867 bioactive agent Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
208000015114 central nervous system disease Diseases 0.000 description 2
229960003920 cocaine Drugs 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
230000006735 deficit Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
208000024732 dysthymic disease Diseases 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
230000006870 function Effects 0.000 description 2
206010020765 hypersomnia Diseases 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
239000012907 medicinal substance Substances 0.000 description 2
239000012803 melt mixture Substances 0.000 description 2
230000036651 mood Effects 0.000 description 2
210000001577 neostriatum Anatomy 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
235000020232 peanut Nutrition 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
208000020016 psychiatric disease Diseases 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000001878 scanning electron micrograph Methods 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000010512 thermal transition Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
206010001540 Akathisia Diseases 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
206010003225 Arteriospasm coronary Diseases 0.000 description 1
208000021465 Brief psychotic disease Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
206010011091 Coronary artery thrombosis Diseases 0.000 description 1
206010011971 Decreased interest Diseases 0.000 description 1
208000024254 Delusional disease Diseases 0.000 description 1
101100421425 Drosophila melanogaster Sply gene Proteins 0.000 description 1
206010016374 Feelings of worthlessness Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010020710 Hyperphagia Diseases 0.000 description 1
206010022562 Intermittent claudication Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
241000840267 Moma Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
206010028391 Musculoskeletal Pain Diseases 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
241000009328 Perro Species 0.000 description 1
241000288906 Primates Species 0.000 description 1
206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
208000011963 Substance-induced psychotic disease Diseases 0.000 description 1
231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 1
206010042458 Suicidal ideation Diseases 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
231100000230 acceptable toxicity Toxicity 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229940025084 amphetamine Drugs 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
239000003693 atypical antipsychotic agent Substances 0.000 description 1
229940127236 atypical antipsychotics Drugs 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229920000229 biodegradable polyester Polymers 0.000 description 1
239000004622 biodegradable polyester Substances 0.000 description 1
238000006065 biodegradation reaction Methods 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000013267 controlled drug release Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
201000011634 coronary artery vasospasm Diseases 0.000 description 1
208000002528 coronary thrombosis Diseases 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
235000019788 craving Nutrition 0.000 description 1
208000026725 cyclothymic disease Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000003001 depressive effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
238000001938 differential scanning calorimetry curve Methods 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009513 drug distribution Methods 0.000 description 1
208000010118 dystonia Diseases 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
230000001505 hypomanic effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000009434 installation Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
208000021156 intermittent vascular claudication Diseases 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010902 jet-milling Methods 0.000 description 1
238000009533 lab test Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
201000003995 melancholia Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
239000011812 mixed powder Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
238000000465 moulding Methods 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000001722 neurochemical effect Effects 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
239000003076 neurotropic agent Substances 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
239000012053 oil suspension Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
238000000879 optical micrograph Methods 0.000 description 1
238000000399 optical microscopy Methods 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
235000020830 overeating Nutrition 0.000 description 1
208000002851 paranoid schizophrenia Diseases 0.000 description 1
238000003921 particle size analysis Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000008447 perception Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
238000012667 polymer degradation Methods 0.000 description 1
-1 polyphosphoesters Polymers 0.000 description 1
230000003334 potential effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000011808 rodent model Methods 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
208000022610 schizoaffective disease Diseases 0.000 description 1
230000001932 seasonal effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000004911 serous fluid Anatomy 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000007873 sieving Methods 0.000 description 1
208000022925 sleep disturbance Diseases 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
238000012549 training Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Hydrogenated Pyridines (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Biological Depolymerization Polymers (AREA)

UA2001064165A 1998-12-16 1999-11-22 Antagonist of serotonin receptor encapsulated by biodegradable polymer and method for its manufacture UA73101C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US21298698A	1998-12-16	1998-12-16
PCT/US1999/027705 WO2000035423A1 (en)	1998-12-16	1999-11-22	Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same

Publications (1)

Publication Number	Publication Date
UA73101C2 true UA73101C2 (en)	2005-06-15

Family

ID=22793267

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2001064165A UA73101C2 (en)	1998-12-16	1999-11-22	Antagonist of serotonin receptor encapsulated by biodegradable polymer and method for its manufacture

Country Status (35)

Country	Link
EP (1)	EP1140026B1 (et)
JP (1)	JP4759141B2 (et)
KR (1)	KR100707710B1 (et)
CN (1)	CN1195497C (et)
AP (1)	AP1769A (et)
AR (1)	AR021652A1 (et)
AT (1)	ATE303795T1 (et)
AU (1)	AU770673B2 (et)
BG (1)	BG65500B1 (et)
BR (1)	BR9916276A (et)
CA (1)	CA2355077C (et)
CR (1)	CR6424A (et)
CZ (1)	CZ301947B6 (et)
DE (1)	DE69927177T2 (et)
DK (1)	DK1140026T3 (et)
EA (1)	EA004502B1 (et)
EE (1)	EE200100314A (et)
ES (1)	ES2245128T3 (et)
HK (1)	HK1041645B (et)
HR (1)	HRP20010446A2 (et)
HU (1)	HU226586B1 (et)
ID (1)	ID28909A (et)
IL (2)	IL143761A0 (et)
ME (2)	MEP19408A (et)
NO (1)	NO20012981L (et)
NZ (1)	NZ511962A (et)
OA (1)	OA11728A (et)
PL (1)	PL196822B1 (et)
RS (1)	RS50123B (et)
SK (1)	SK285812B6 (et)
TR (1)	TR200101759T2 (et)
TW (1)	TWI221418B (et)
UA (1)	UA73101C2 (et)
WO (1)	WO2000035423A1 (et)
ZA (1)	ZA200104899B (et)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10061932A1 (de) *	2000-12-13	2002-10-24	Pharmatech Gmbh	Wirkstoffhaltige Mikropartikel und Verfahren zur Herstellung der Mikropartikel durch Abrasion
AU2002256694A1 (en) *	2001-03-20	2002-10-03	Euroscreen S.A.	Screening, diagnostic and/or dosage method and device of an agonist and/or antagonist for a calcium-coupled receptor
SK14182003A3 (sk) *	2001-05-23	2004-05-04	Hexal Ag	Homogenizát pre implantáty a mikročastice
US20050215561A1 (en) *	2004-03-19	2005-09-29	Krishnendu Ghosh	Pharmaceutical dosage forms and compositions
KR20070059161A (ko) *	2004-09-21	2007-06-11	산동 루예 파마슈티칼 컴파니 리미티드	도파민 수용체 효능제를 함유하는 장시간 작용 서방성 제제및 그 제조방법
US8377453B2 (en)	2008-03-11	2013-02-19	Depomed, Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en)	2008-03-11	2013-02-12	Depomed, Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
BRPI0913724B8 (pt) *	2008-09-18	2021-05-25	Purdue Pharma Lp	formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo
US20100291214A1 (en) *	2008-12-23	2010-11-18	Armark Authentication Technologies, Llc	Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
WO2010151746A2 (en) *	2009-06-26	2010-12-29	Armark Authentication Technologies, Llc	Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US8597681B2 (en)	2009-12-22	2013-12-03	Mallinckrodt Llc	Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en)	2009-12-22	2015-12-01	Mallinckrodt Llc	Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8858963B1 (en)	2011-05-17	2014-10-14	Mallinckrodt Llc	Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en)	2011-05-17	2014-06-03	Mallinckrodt Llc	Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en)	2011-05-17	2015-06-09	Mallinckrodt Llc	Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US20160193151A1 (en) *	2015-01-06	2016-07-07	Maria Del Pilar Noriega Escobar	Dosage form incorporating an amorphous drug solid solution
US11672755B2 (en) *	2019-12-31	2023-06-13	Wanka Tanka Ltd.	Extended release plastic formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4389330A (en) *	1980-10-06	1983-06-21	Stolle Research And Development Corporation	Microencapsulation process
DE3612212A1 (de) *	1986-04-11	1987-10-15	Basf Ag	Verfahren zur herstellung von festen pharmazeutischen formen
US5439688A (en) *	1989-07-28	1995-08-08	Debio Recherche Pharmaceutique S.A.	Process for preparing a pharmaceutical composition
CH679207A5 (et) *	1989-07-28	1992-01-15	Debiopharm Sa
DK0528978T3 (da) *	1990-05-16	2003-02-17	Southern Res Inst	Mikrokapsler til reguleret afgivelse og deres anvendelse i stimulering af nervefibervækst
KR100211713B1 (ko) *	1990-06-01	1999-08-02	슈테펜 엘. 네스비트	(+)-알파-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올
GB9016885D0 (en) *	1990-08-01	1990-09-12	Scras	Sustained release pharmaceutical compositions
KR0182801B1 (ko) *	1991-04-16	1999-05-01	아만 히데아키	고체 분산체의 제조방법
US5505963A (en) *	1993-04-07	1996-04-09	Schwartz Pharma Ag	Slow release pharmaceutical preparation
US5456917A (en) *	1993-04-12	1995-10-10	Cambridge Scientific, Inc.	Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
AU4467396A (en) *	1994-12-12	1996-07-10	Omeros Medical Systems, Inc.	Irrigation solution and method for inhibition of pain, inflammation and spasm

1999
- 1999-11-22 DK DK99960556T patent/DK1140026T3/da active
- 1999-11-22 WO PCT/US1999/027705 patent/WO2000035423A1/en not_active Ceased
- 1999-11-22 SK SK828-2001A patent/SK285812B6/sk not_active IP Right Cessation
- 1999-11-22 AU AU17425/00A patent/AU770673B2/en not_active Ceased
- 1999-11-22 EP EP99960556A patent/EP1140026B1/en not_active Expired - Lifetime
- 1999-11-22 AT AT99960556T patent/ATE303795T1/de active
- 1999-11-22 BR BR9916276-8A patent/BR9916276A/pt not_active Application Discontinuation
- 1999-11-22 PL PL348233A patent/PL196822B1/pl not_active IP Right Cessation
- 1999-11-22 EA EA200100551A patent/EA004502B1/ru not_active IP Right Cessation
- 1999-11-22 ME MEP-194/08A patent/MEP19408A/xx unknown
- 1999-11-22 CZ CZ20012157A patent/CZ301947B6/cs not_active IP Right Cessation
- 1999-11-22 ME MEP-2008-194A patent/ME00066B/me unknown
- 1999-11-22 HU HU0105048A patent/HU226586B1/hu not_active IP Right Cessation
- 1999-11-22 JP JP2000587744A patent/JP4759141B2/ja not_active Expired - Fee Related
- 1999-11-22 IL IL14376199A patent/IL143761A0/xx active IP Right Grant
- 1999-11-22 AP APAP/P/2001/002198A patent/AP1769A/en active
- 1999-11-22 UA UA2001064165A patent/UA73101C2/uk unknown
- 1999-11-22 KR KR1020017007561A patent/KR100707710B1/ko not_active Expired - Fee Related
- 1999-11-22 NZ NZ511962A patent/NZ511962A/xx not_active IP Right Cessation
- 1999-11-22 ID IDW00200101296A patent/ID28909A/id unknown
- 1999-11-22 TR TR2001/01759T patent/TR200101759T2/xx unknown
- 1999-11-22 CA CA002355077A patent/CA2355077C/en not_active Expired - Fee Related
- 1999-11-22 HR HR20010446A patent/HRP20010446A2/hr not_active Application Discontinuation
- 1999-11-22 EE EEP200100314A patent/EE200100314A/et unknown
- 1999-11-22 RS YUP-414/01A patent/RS50123B/sr unknown
- 1999-11-22 DE DE69927177T patent/DE69927177T2/de not_active Expired - Lifetime
- 1999-11-22 HK HK02103401.5A patent/HK1041645B/zh not_active IP Right Cessation
- 1999-11-22 OA OA1200100150A patent/OA11728A/en unknown
- 1999-11-22 ES ES99960556T patent/ES2245128T3/es not_active Expired - Lifetime
- 1999-11-22 CN CNB998145831A patent/CN1195497C/zh not_active Expired - Fee Related
- 1999-12-10 TW TW088121702A patent/TWI221418B/zh not_active IP Right Cessation
- 1999-12-14 AR ARP990106345A patent/AR021652A1/es unknown
2001
- 2001-06-12 BG BG105591A patent/BG65500B1/bg unknown
- 2001-06-14 IL IL143761A patent/IL143761A/en not_active IP Right Cessation
- 2001-06-14 ZA ZA200104899A patent/ZA200104899B/en unknown
- 2001-06-15 NO NO20012981A patent/NO20012981L/no not_active Application Discontinuation
- 2001-07-16 CR CR6424A patent/CR6424A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20010082359A (ko)	2001-08-29
CR6424A (es)	2004-02-26
CZ20012157A3 (cs)	2001-09-12
BG65500B1 (bg)	2008-10-31
EP1140026B1 (en)	2005-09-07
PL348233A1 (en)	2002-05-20
YU41401A (sh)	2003-12-31
HUP0105048A3 (en)	2002-09-30
MEP19408A (en)	2010-06-10
AU770673B2 (en)	2004-02-26
AR021652A1 (es)	2002-07-31
EA200100551A1 (ru)	2001-10-22
HK1041645A1 (en)	2002-07-19
CN1330536A (zh)	2002-01-09
CA2355077C (en)	2009-05-26
ID28909A (id)	2001-07-12
PL196822B1 (pl)	2008-02-29
SK285812B6 (sk)	2007-08-02
RS50123B (sr)	2009-03-25
HK1041645B (zh)	2005-07-29
EE200100314A (et)	2002-08-15
DK1140026T3 (da)	2006-01-02
NO20012981L (no)	2001-07-27
ATE303795T1 (de)	2005-09-15
WO2000035423A1 (en)	2000-06-22
DE69927177D1 (de)	2005-10-13
JP4759141B2 (ja)	2011-08-31
ES2245128T3 (es)	2005-12-16
TWI221418B (en)	2004-10-01
NZ511962A (en)	2003-06-30
EA004502B1 (ru)	2004-04-29
NO20012981D0 (no)	2001-06-15
JP2002532408A (ja)	2002-10-02
TR200101759T2 (tr)	2001-12-21
OA11728A (en)	2005-02-01
SK8282001A3 (en)	2001-11-06
HUP0105048A2 (hu)	2002-05-29
HRP20010446A2 (en)	2002-06-30
CZ301947B6 (cs)	2010-08-11
KR100707710B1 (ko)	2007-04-18
IL143761A (en)	2006-08-01
BR9916276A (pt)	2001-09-04
AP1769A (en)	2007-08-22
AU1742500A (en)	2000-07-03
DE69927177T2 (de)	2006-06-08
IL143761A0 (en)	2002-04-21
WO2000035423A9 (en)	2002-08-22
BG105591A (en)	2002-01-31
CN1195497C (zh)	2005-04-06
EP1140026A1 (en)	2001-10-10
AP2001002198A0 (en)	2001-09-30
CA2355077A1 (en)	2000-06-22
HU226586B1 (en)	2009-04-28
ME00066B (me)	2010-06-10
ZA200104899B (en)	2002-09-16

Publication	Publication Date	Title
UA73101C2 (en)	2005-06-15	Antagonist of serotonin receptor encapsulated by biodegradable polymer and method for its manufacture
US6455526B1 (en)	2002-09-24	Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
EP2968320B1 (en)	2020-11-11	Organic compounds
HU211845A9 (en)	1995-12-28	Orally administrated solvent-free pharmaceutical composition with delayed active-substance release and a method for preparing thereof
Jedinger et al.	2016	Development of an abuse-and alcohol-resistant formulation based on hot-melt extrusion and film coating
Xu et al.	2021	Porous core/dense shell PLA microspheres embedded with high drug loading of bupivacaine crystals for injectable prolonged release
CA3023795C (en)	2024-01-16	Use of an amino sugar as plasticizer
US4902516A (en)	1990-02-20	Binder-free granules with delayed release of the active compound
Tamaddon et al.	2015	Thermoanalytical characterization of clindamycin-loaded intravitreal implants prepared by hot melt extrusion
DE3701625A1 (de)	1988-08-04	Perorale arzneimittelzubereitung mit verzoegerter wirkstofffreigabe
MXPA01005920A (es)	2001-12-13	Antagonista del receptor de serotonina encapsulada de polimero biodegradable y metodo para preparar el mismo
JP2003522097A (ja)	2003-07-22	可溶化デリバリーシステムおよび製造方法
KR102793673B1 (ko)	2025-04-11	바리시티닙을 포함하는 장기지속형 미립구의 제조 방법 및 이의 제조 방법으로 제조된 바리시티닙을 포함하는 장기지속형 미립구
Chaw et al.	2003	Design of physostigmine-loaded polymeric microparticles for pretreatment against exposure to organophosphate agents
Alqahtani	2021	Controlled release oral dosage forms using functional additives in hot melt extruded pharmaceuticals
Nunes	2020	Preparation of drug loaded biodegradable films
HK1220615B (en)	2021-07-30	Organic compounds
GGLLGGGGGG	0	GGLGLGLGLSS GGGLGG LGGGLGGGGG LGGGGGG SLLLLaaLLL S LLLL STRENGTH